# NOVOCURE LTD (NVCR)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/NVCR/

- Reporting holders: 6
- Reported value: $399.0K
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Versant Capital Management, Inc](https://holderbook.com/funds/1735057-versant-capital-management-inc/) | $314.7K | 19,729 | 0.0% | 11 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $33.2K | 2,083 | 0.0% | 14 |
| [ELEVATION WEALTH PARTNERS, LLC](https://holderbook.com/funds/1976256-elevation-wealth-partners-llc/) | $27.6K | 1,731 | 0.0% | 5 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $14.6K | 918 | 0.0% | 12 |
| [GoalVest Advisory LLC](https://holderbook.com/funds/1839307-goalvest-advisory-llc/) | $8.1K | 507 | 0.0% | 1 |
| [TOMPKINS FINANCIAL CORP](https://holderbook.com/funds/1005817-tompkins-financial-corp/) | $798 | 50 | 0.0% | 19 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 6 | $399.0K |
| Q2 2026 | 221 | $1.7B |
| Q1 2026 | 225 | $1.1B |
| Q4 2025 | 239 | $1.3B |
| Q3 2025 | 247 | $1.2B |
| Q2 2025 | 246 | $1.7B |
| Q1 2025 | 231 | $1.7B |
| Q4 2024 | 246 | $2.8B |
| Q3 2024 | 225 | $1.5B |
| Q2 2024 | 236 | $1.6B |
| Q1 2024 | 235 | $1.5B |
| Q4 2023 | 219 | $1.4B |